Predictors of antibody persistence to the 7-valent pneumococcal conjugate vaccine in healthy Fijian infants at 12 months of age

被引：0
|
作者：
Lindholm, Daniel E. [1 ,2 ]
Licciardi, Paul, V [1 ,2 ]
Ratu, Felisita T. [1 ]
Mulholland, E. Kim [1 ,3 ]
Nguyen, Cattram D. [1 ,4 ]
Russell, Fiona M. [1 ,2 ]
机构：
[1] Murdoch Childrens Res Inst MCRI, Infect & Immun, Melbourne, Vic, Australia
[2] Univ Melbourne, Ctr Int Child Hlth, Dept Paediat, Melbourne, Vic, Australia
[3] London Sch Hyg & Trop Med, London, England
[4] Murdoch Childrens Res Inst, Clin Epidemiol & Biostat Unit, Melbourne, Vic, Australia
来源：
VACCINE | 2020年 / 38卷 / 33期
关键词：
Pneumococcal conjugate vaccine; Poor antibody persistence; Ethnicity; Reduced-dose schedule; Fiji; Infant; NASOPHARYNGEAL CARRIAGE; POLYSACCHARIDE VACCINE; IMMUNE-RESPONSES; CHILDREN; IMPACT;
D O I：
10.1016/j.vaccine.2020.06.025
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Little is known about the predictors of antibody persistence to pneumococcal conjugate vaccines (PCV) in the context of reduced dose schedules. In Fiji, an RCT investigated 0, 1, 2 and 3 dose schedules of 7-valent PCV administered at 6, 10 and 14 weeks of age in 364 healthy infants. This study was a post-hoc analysis of the predictors of poor antibody persistence at 12 months, prior to a booster, using univariable and multivariable analyses. The strongest predictors of poor antibody persistence as measured by serotype-specific immunoglobulin G (IgG) and opsonophagocytosis (OI) assays were being of Indigenous Fijian ethnicity (IgG: adjusted odds ratio (aOR) 3.43, p < 0.001; OI: aOR 1.96, p = 0.013) and receipt of fewer than 3 doses of PCV. These findings may help to identify which children may be at an increased risk of pneumococcal disease in the context of reduced dose primary series PCV schedules. (C) 2020 Elsevier Ltd. All rights reserved.
引用
收藏
页码：5095 / 5099
页数：5
相关论文
共 50 条
  • [41] Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months
    Russell, F. M.
    Balloch, A.
    Licciardi, P. V.
    Carapetis, J. R.
    Tikoduadua, L.
    Waqatakirewa, L.
    Cheung, Y. B.
    Mulholland, E. K.
    Tang, M. L. K.
    VACCINE, 2011, 29 (27) : 4499 - 4506
  • [42] Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens
    Mahon, BE
    Hsu, K
    Karumuri, S
    Kaplan, SL
    Mason, EO
    Pelton, SI
    VACCINE, 2006, 24 (14) : 2514 - 2520
  • [43] Immune response to the 7-valent pneumococcal conjugate vaccine in 30 asplenic children
    Mikoluc, B.
    Kayhty, H.
    Bernatowska, E.
    Motkowski, R.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2008, 27 (10) : 923 - 928
  • [44] A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults
    French, Neil
    Gordon, Stephen B.
    Mwalukomo, Thandie
    White, Sarah A.
    Mwafulirwa, Gershom
    Longwe, Herbert
    Mwaiponya, Martin
    Zijlstra, Eduard E.
    Molyneux, Malcolm E.
    Gilks, Charles F.
    MALAWI MEDICAL JOURNAL, 2016, 28 (03) : 115 - 122
  • [45] Nearly Complete Elimination of the 7-valent Pneumococcal Conjugate Vaccine Serotypes in Tennessee
    Halasa, Natasha B.
    Grijalva, Carlos G.
    Arbogast, Patrick G.
    Talbot, Thomas R.
    Craig, Allen S.
    Griffin, Marie R.
    Schaffner, William
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2013, 32 (06) : 604 - 609
  • [46] Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, Australia
    Littlejohn, E. S.
    Clothier, H. J.
    Perrett, K. P.
    Danchin, M.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (07) : 1828 - 1835
  • [47] Impact of the 7-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Infants Younger Than 90 Days in England and Wales
    Ladhani, Shamez N.
    Andrews, Nick J.
    Waight, Pauline
    Borrow, Ray
    Slack, Mary P. E.
    Miller, Elizabeth
    CLINICAL INFECTIOUS DISEASES, 2013, 56 (05) : 633 - 640
  • [48] Pneumococcal Nasopharyngeal Carriage following Reduced Doses of a 7-Valent Pneumococcal Conjugate Vaccine and a 23-Valent Pneumococcal Polysaccharide Vaccine Booster
    Russell, F. M.
    Carapetis, J. R.
    Satzke, C.
    Tikoduadua, L.
    Waqatakirewa, L.
    Chandra, R.
    Seduadua, A.
    Oftadeh, S.
    Cheung, Y. B.
    Gilbert, G. L.
    Mulholland, E. K.
    CLINICAL AND VACCINE IMMUNOLOGY, 2010, 17 (12) : 1970 - 1976
  • [49] Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine
    Millar, Eugene V.
    O'Brien, Katherine L.
    Bronsdon, Melinda A.
    Madore, Dace
    Hackell, Jill G.
    Reid, Raymond
    Santosham, Mathuram
    CLINICAL INFECTIOUS DISEASES, 2007, 44 (09) : 1173 - 1179
  • [50] Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection
    Tarragó, D
    Casal, J
    Ruiz-Contreras, J
    Ramos, JT
    Rojo, P
    Snippe, H
    Jansen, WTM
    CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2005, 12 (01) : 165 - 170
12345